In a multicenter pilot study, 32 patients showing steroidresistant acute graft-versus-host disease (GVHD) were treated by in vivo administration of anti-interleukin-2 (IL-2) receptor monoclonal antibody (MoAb B-BIOI. Twentythree patients received marrow from HLA-matched related donors, four from matched unrelated donors and five from partially matched related donors. The overall grade of GVHD was II in 16 patients, 111 in two, and IV in five. Five milligrams of B-B10 MoAb was infused in bolus daily for 10 days and then every second day for a further 10 days in an attempt t o reduce GVHD recurrence. No clinical side effects were noted during the B-B10 treatment period. A complete response (CR) acute GVHD was achieved in 21 patients (65.6%). Six patients (1 8.7%) showed partial improvement (PR) and 5 patients (15.6%) no response (NR). A significant factor associated with GVHD response RAFT-VERSUS-HOST disease (GVHD) remains a G major complication in allogeneic bone marrow transplantation (BMT). It is the primary or contributory cause of death in about 20% of transplant recipients. Drugs currently used in the prophylaxis and treatment of GVHD are nonspecific immunosuppressive agents.' Over the last decade, a considerable effort has been made to reduce GVHD frequency and severity. Combinations of drugs, eg, methotrexate (MTX) plus cyclosporin (CSP) or CSP plus prednisone,' have reduced GVHD incidence to about 20% to 25% in HLA-identical related transplants. T-cell depletion (TCD) raised the hopes of BMT teams, given the substantial decrease in GVHD incidence, but the true value of TCD remains questionable due to the increased risk of graft failure and leukemia relapse.* In spite of clear improvements in GVHD prophylaxis, many patients experience severe steroid-resistant GVHD, frequently resulting in death. High-dose methylprednisolone has been shown to be effective in the treatment of severe acute GVHD; 30% to 40% of patients showed improvement chiefly in skin and gut manifestation^.^ In other series, treatment of severe acute GVHD has involved the combination of CSP and antilymphocyte globulins (ATG), either with or without methylprednisolone. Improvement was shown in 30% of these patient^.^ Viral, bacterial, and fungal infections were the major causes of death in these groups of patients, and interstitial pneumonia was more frequent.
In a multicenter pilot study, 32 patients showing steroidresistant acute graft-versus-host disease (GVHD) were treated by in vivo administration of anti-interleukin-2 (IL-2) receptor monoclonal antibody (MoAb B-BIOI. Twentythree patients received marrow from HLA-matched related donors, four from matched unrelated donors and five from partially matched related donors. The overall grade of GVHD was II in 16 patients, 111 in two, and IV in five. Five milligrams of B-B10 MoAb was infused in bolus daily for 10 days and then every second day for a further 10 days in an attempt t o reduce GVHD recurrence. No clinical side effects were noted during the B-B10 treatment period. A complete response (CR) acute GVHD was achieved in 21 patients (65.6%). Six patients (1 8.7%) showed partial improvement (PR) and 5 patients (15.6%) no response (NR). A significant factor associated with GVHD response RAFT-VERSUS-HOST disease (GVHD) remains a G major complication in allogeneic bone marrow transplantation (BMT). It is the primary or contributory cause of death in about 20% of transplant recipients. Drugs currently used in the prophylaxis and treatment of GVHD are nonspecific immunosuppressive agents.' Over the last decade, a considerable effort has been made to reduce GVHD frequency and severity. Combinations of drugs, eg, methotrexate (MTX) plus cyclosporin (CSP) or CSP plus prednisone,' have reduced GVHD incidence to about 20% to 25% in HLA-identical related transplants. T-cell depletion (TCD) raised the hopes of BMT teams, given the substantial decrease in GVHD incidence, but the true value of TCD remains questionable due to the increased risk of graft failure and leukemia relapse.* In spite of clear improvements in GVHD prophylaxis, many patients experience severe steroid-resistant GVHD, frequently resulting in death. High-dose methylprednisolone has been shown to be effective in the treatment of severe acute GVHD; 30% to 40% of patients showed improvement chiefly in skin and gut manifestation^.^ In other series, treatment of severe acute GVHD has involved the combination of CSP and antilymphocyte globulins (ATG), either with or without methylprednisolone. Improvement was shown in 30% of these patient^.^ Viral, bacterial, and fungal infections were the major causes of death in these groups of patients, and interstitial pneumonia was more frequent.
The recent development of monoclonal antibodies (MoAbs) directed against the cells mediating the alloreaction in organ and tissue transplantation possibly allows for more specific therapy.'-'' Activated T cells express two distinct interleukin-2 (IL-2) binding entities: one of 55 Kd and one of 75 Kd. These two receptor molecules show low and intermediate affinity for IL-2, respectively. The high affinity IL-2 receptor (IL-2R) corresponds to a membrane heterodimer comprising the two subunits noncovalently associated."J' In experimental models, it has been shown that an anti-IL-2R antibody could be used to prevent or treat acute GVHD in mice and rat^.'^.'^ was the delay between the onset of the GVHD and the first day of B-B10 infusion. The earlier B-B10 was introduced, the greater the probability of CR ( P = .03). There was no correlation between the serum B-B10 level and GVHD response (P = .69). There was, however, a significant correlation between the clinical response and the B-B10 kinetics as a function of time: serum B-B10 levels attained a plateau level more rapidly in the CR group than in the PR/NR group. Among the 26 complete and partial evaluable responders, GVHD recurred in 10 cases (38.4%). Host anti-B-810 MoAb immune response occurred in only one (7.1%) of the 14 An anti-IL-2R MoAb (B-B10) that specifically binds to activated T cells has been developed in our laboratory." It inhibits the IL-2-induced proliferation of phytohemagglutinin (PHA)/T cells and of T cells in the mixed lymphocyte reaction. It recognizes an epitope on the IL-2R that is close to that recognized by the MoAbs directed at CD25.
The potential beneficial effect of B-B10 as second-line therapy has been assessed in a multicenter cooperative pilot study for the treatment of steroid-resistant acute GVHD. The encouraging preliminary results observed in the first 10 patients18 led us to conduct the phase I1 study in a total of 32 patients reported here. fractions analysis was performed using sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and high performance liquid chromatography analysis (Biotest Lab, Dreieich, RFA). Batches of purity greater than 95% were used. The purified MoAb batches were sterilized by passage over a 0.22 pm filter and were shown to be nonpyrogenic and sterile (Centre Regional de Transfusion, Strasbourg, France). Each batch was controlled for the absence of murine viral contamination (University of Nijmegen, The Netherlands) and low DNA concentration (510 pg/mL). The MoAb was stable after heat treatment, a 10 times freezing cycle, and lyophylization process. The MoAb was prepared at 1 mg/mL PBS, pH 7.4 with 4% human albumin and supplied in 5 mL ampules for clinical use. The biological properties of B-B10 have been previously reported.I7
PATIENTS AND METHODS

Monoclonal
Patients. From January 1988 to March 1989 at nine French BMT centres, 32 patients entered this pilot study. Their clinical characteristics are summarized in Table 1 . Twenty-three patients received marrow from HLA-matched related donors (MRD), four from matched unrelated donors (MUD), and five from partially matched related donors (PMRD, three with one incompatible locus and two with three incompatible loci). The patients were transplanted using different preparative regimen, including cyclophosphamide (CY; n = 14) or high-dose melphalan (n = 2) plus fractionated total body irradiation (TBI; range, 12 to 14 Cy); high-dose cytarabine plus high-dose melphalan plus TBI (n = 4); CY plus etoposide (VP 16) plus carmustine (BCNU) plus TBI (n = 3); busulfan plus CY (n = 7). In addition, two patients grafted for severe aplastic anemia received CY followed by a thoracoabdominal irradiation. All patients were nursed under strict protective isolation using laminar air-flow or closed plastic bubble systems. To prevent GVHD, 22 patients received cyclosporin (CSP) plus MTX according to an established regimen,' seven patients received CSP plus prednisone, and two patients received CSP alone. Only one patient received T-lymphocyte-depleted donor marrow. Acute GVHD was diagnosed and graded from I1 to IV according to the Seattle criteria" and histologically confirmed by skin biopsy. Grade I1 GVHD occurred in 16 patients, grade I11 in 11 patients, and grade IV in five. Organ involvements are shown in Table 1 . With the development of 2 grade I1 GVHD, patients received prednisolone (2 mg/kg) as first-line therapy (this dose was increased to 3 to 5 mg/kg for patients having previously been treated with CSP plus prednisone). If the syndrome progressed after 2 to 4 days, the GVHD was considered standard dose steroid-resistant. In 12 patients, high-dose methylprednisolone (10 to 20 mg/kg/d) or ALG (three patients) were given as second-line therapy. Patients whose GVHD did not improve received anti-IL-2R MoAb (B-BIO) as third-line therapy. In a group of 20 patients, B-BIO MoAb was given as second-line therapy once steroid resistance was established (less than 12 days after the onset of acute GVHD in the majority of the cases). In all cases, CSP and corticosteroids ( 1 to 2 mg/kg) were maintained during B-BIO administration.
The response of GVHD to B-B10 MoAb treatment fell into three groups: complete response (CR), for patients who resolved in all organs involved; partial response (PR), for patients whose improvement was incomplete (staging decrease of at least one organ involved); no response (NR) for an unchanged status or progressive evolution.
Five milligrams of B-BIO MoAb diluted in 50 to 100 mL of 4% human albumin was infused in bolus (1 5 to 20 minutes) every day for 10 days (first 10 patients) and then every second day for a further 10 days (22 remaining patients) in an attempt to reduce the GVHD recurrence rate. The sera of patients were collected before each infusion for a pharmacokinetics study of the antibody. When no response was observed, B-BIO was nevertheless maintained at least until day 10 on the supposition that a delayed response might occur. The protocol was approved by the B-BZO MoAb treatment protocol.
ethical committee of the University of BesanGon, France. The procedure was explained in detail to patients and family members, and patients were asked to sign informed consent forms.
Circulating B-BIO was measured by serial dilutions in a double sandwich enzyme-linked immunosorbent assay (ELISA) with a sensitivity of 10 ng/mL. Rabbit anti-mouse Ig was coated overnight in carbonate buffer. Control and patient sera were incubated at different dilutions for 1 hour followed by a further incubation for 1 hour with biotinylated goat anti-mouse Ig, and finally by an hour incubation with streptavidin peroxidase. 0-Phenylenediamine served as a substrate and optical density (OD) was measured after 30 minutes at 405 nm.
Patient sera were obtained 1,2, and 3 months after the last B-BIO administration and stored at -2OOC until use. Host antixenogeneic Ig formation was determined by ELISA. B-BIO antibody was coated overnight in carbonate buffer. Controls and patient sera were incubated at different dilutions for 1 hour at room temperature followed by 1 hour with biotinylated goat anti-human Ig and 1 hour with streptavidinperoxidase. Antibody concentration was determined as previously described for B-BIO serum level measurements.
Screening for anti-idiotype antibodies was performed by flow cytometry. Control and patient sera were incubated with biotinylated B-BIO for 15 minutes. PHA/T cells were then added, for 30 minutes at 4OC, followed by a 15 minute-incubation with avidinfluorescein isothiocyanate (FITC). Cells were fixed with paraformaldehyde and the fluorescence intensity measured at 460 nm with a FACScan (Becton-Dickinson, Mountain View, CA).
Soluble IL-2R (sIL-2R) were detected with an ELISA as previously described by Rubin et alFO We used two murine monoclonal anti-IL-2R, BG3 and BF 2,17 that bound to the IL-2R at distinct epitopes. A reference preparation of 1,000 U/mL supernatant from PHA-stimulated peripheral blood lymphocytes was used as a standard.
Seven potential factors that might be associated with the clinical response to B-BIO were studied. We compared each independent variable distribution between the CR group and the PR/NR group. This comparison was performed using the Chi-squared test, the Fisher exact test, and the Mann-Whitney test. The comparison of serum levels of B-BlO between the two groups was performed using analysis of variance for repeated measurements (ANOVA).
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RESULTS
Tolerance of the treatment. No clinical side effects were noted during the B-B10 treatment period. Four patients developed transient leukopenia (0.5 to 0.9 x 109/L white blood cells), which returned to normal between day 6 and day 9 of treatment. One patient developed a thrombocytopenia that persisted even after B-B10 treatment was completed (probably unrelated to the B-B10 treatment but due rather to a GVHD).
A CR was achieved in 2 1 patients (65.6%). Among these, 12 patients had grade I1 GVHD, eight had grade 111, and one grade IV. Six patients (18.7%) showed partial improvement (skin in three patients, skin and liver in one, and skin and gut in two). Three of these patients had grade 11, two had grade 111, and one had grade IV GVHD. Five patients showed no response: one of them had grade 11, one had grade 111, and three had grade IV GVHD. Among the 31 skin, 21 gut, and 14 liver involvements, 26 (83%), 14 (66%), and 9 (64%), respectively, responded to B-BlO administration. It must be emphasized, however, that the liver response is often difficult to assess.
Response to B-BI 0 treatment. Table 2 shows a univariate analysis of the influence of clinical parameters on the clinical response to B-B10. No correlation was observed between HLA identity of donor and recipient and the clinical response to the MoAb. Of 21 CR, there were two mismatched and four matched unrelated BMT recipients. Among the 11 PR and NR, there were three mismatched BMT. However, a significant factor associated with GVHD response was the delay between onset of acute GVHD and the first day of B-BlO treatment (P = .03). In the CR group, the mean delay was 10.6 days (in 16 of 21 patients it was less than 15 days); in the PR/NR group, it was 37 days (in 4 of 11 patients it was less than 15 days, 3 of them being grafted from a MRD and one from a PMRD). The time lapse between BMT and the onset of acute GVHD was on average 29 days for the CR group and 22 days for the NR/PR group. The onset of GVHD occurred at 15 days or less in 38% of the CR group and 63% of the cases in the NR/PR group. This may suggest a correlation of response with time of onset (and not only with delay of treatment after onset).
Of the 14 patients analyzed by ELISA and flow cytometry, only one developed anti-isotypic antibodies against B-BlO (7.1%).
Among the 26 evaluable complete and partial responders, GVHD recurred in 10 cases (38.4%). In the first group of nine evaluable patients who were treated with B-B10 5 mg/d for 10 days, four GVHD relapses occurred (44%). In the second group of 17 evaluable patients for whom the B-BlO treatment was maintained until day 20 to limit GVHD recurrence, it recurred in six cases (35%; P = .74). Of the 10 patients with GVHD recurrence, additional immunosuppressive treatment (second course of B-B 1 O, ALG, high-dose methylprednisolone) was beneficial in four patients but was ineffective in six. Of these 10 patients, 8 had a GVHD of grades I11 or IV, and 9 were grafted from a Host anti-B-BlO MoAb immune response. MRD. The average interval between the onset of GVHD and B-B10 treatment was 23.2 days (range, 2 to 58 days). In seven patients the interval was longer than 15 days. Chronic GVHD occurred in 10 of 17 (58%) evaluable patients who survived more than 100 days after transplantation. Among these, five patients showed an extensive disease. Figure 1 shows the mean values of B-B10 sera levels during the first 10 days of treatment with B-B10 5 mg/d in the CR and PR/NR groups. Although there was a trend towards higher levels in responding patients, the correlation was not statistically significant (P = .69). However, if the kinetics of B-B10 was analyzed for each patient individually, it appeared that an antibody concentration higher than 2 pg/mL was reached between day 2 and day 4 in 12 patients of the CR group (57%) as compared with three patients in the PR/NR group (27%). Furthermore, the gradient of the serum B-B10 concentration curve as a function of time showed a statistically significant correlation with the clinical response: B-B 10 levels achieved a plateau level more rapidly in the CR group than in the PR/NR group (P < .0001). The IL-2R serum level was high at the beginning of the B-BlO treatment (3,285 k 2,201 U/mL in the CR group and 2,002 2,556 U/mL in the PR/NR group, compared with 41 1 + 171 U/mL in normal controls).
GVHD recurrence.
B-BlO treatment led to a 20% to 40% decrease in the sIL-2R serum levels irrespective of the GVHD response."
Of the 32 patients, 14 (43.7%) are currently alive between 60 and 420 days after GVHD treatment with B-BlO was completed. Eighteen died between 15 and 172 days (median 69 days) after the first administration of B-B10. The causes of death include GVHD alone in five patients, GVHD with viral or fungal infections in four, interstitial pneumonia in three, sepsis in two, leukoencephalopathy in one, veno-occlusive disease in one, hemolytic uremic syndrome in one, and relapse of leukemia in another.
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DISCUSSION
The in vivo use of a MoAb directed at the IL-2R should rationally be less immunosuppressive. An anti-IL-2R MoAb inhibits the proliferation of only activated IL-24ependent T cell. Contrarily, pan-T MoAbs (CD3, CD5, CD7) react with all T lymphocytes, thus resulting in a more general immunosuppression, increasing the risk of a higher incidence rate of infections and B cell lymphoproliferative disorders. The evaluation of clinical efficacy is dependent on numerous factors, including the diagnostic criteria of GVHD, ie, the clinical symptoms (which are not always reliable) and histopathological gradings. The clinician has to decide whether symptoms are related solely to GVHD or are of infectious or drug origin. The disappearance of skin manifestations, the normalization of gut function, a significant decrease in hyperbilirubinemia during treatment, and general improvement in the patient's status are important parameters on which the assessment of the impact of treatment on GVHD is based.
The administration of MoAb B-B10 was well-tolerated and had a clear anti-GVHD effect (84% responses were either total or partial), even with severe forms of GVHD, (9 
0
-f I -CR were observed among 16 patients with grades 111 to IV), including GVHD of the gut. The efficacy of B-B10 appeared to be closely related to the time delay between onset of GVHD and B-BlO administration: the earlier B-B10 is given, the greater the probability of CR. Of the 20 patients treated with B-BlO within less than 15 days of GVHD onset, 16 (80%) achieved CR, while among eight patients treated after a delay of more than 30 days, only two showed CR (25%).
Although absolute serum levels of B-B10, did not correlate with treatment response, there was a positive correlation of responses with the rate at which B-B10 serum levels reached a plateau. Therefore, in our current protocol, 10 mg B-B10 is given during the first 3 days of treatment, and then the B-B10 dose is adjusted to maintain serum concentrations above 2 pg/mL. The initial dose level is also justifiable when one considers the considerable protein loss in cases of severe diarrhea. In one patient, 40% of B-BlO given was found in the stools. In six patients (not included in this study) who received 10 mg B-BlO during the first 3 days, the B-BlO serum level averaged 4.29 pg/mL (range, 2.3 to 7.8 pg/mL).
One of the major problems encountered in this pilot study was the recurrence of GVHD after immunotherapy was discontinued (34.6%). Among 10 patients treated with B-B10 for 10 days, the incidence was 44%, therefore in subsequent patients treatment was extended to 20 days (5 mg B-BlO/d every other day on days 11-20). Nevertheless GVHD recurred in 35%.
Although sIL-2R serum levels are particularly high in GVHD, infectious complications, especially of viral etiology, can also influence these levels.21 Circulating sIL-2R might block the effectiveness of the antibody and justify the infusion of larger quantities of the antibody. However, we observed no relationship between sIL-2R serum level and GVHD response to B-B10; the dose of B-B10 was not adjusted to the sIL-2R levels. Anti-B-B10 antibody develop- In other pilot studies using MoAbs such as CD8,24 CD5 + CD8 (J. Pico, personal communication, June, 1988) , and CD7 and CD5 conjugated to ricin A chain i m m~n o t o x i n , *~~~~ the complete responses ranged from 30% to 40%, with the best responses occurring in the skin. In all patients, the MoAb was well tolerated. The present study suggests that the therapeutic efficacy of anti-IL-2R MoAb B-B10 is comparable with or superior to that observed with previously used antibodies.
Because of the potential therapeutic advantages of B-B 10, we are currently undertaking a double blind randomized multicenter clinical trial of B-BlO in patients with acute GVHD. The object of this study is to compare the efficacy of B-B 10 in association with methylprednisolone with methylprednisolone alone in the treatment of grade 211 acute GVHD.
We have not investigated whether MoAb B-B10 might also be beneficial in the prevention of GVHD. However, other anti-IL-2R MoAbs (CD25/33B3-1) were used by other investigators as GVHD prophylaxis in a pilot study of four patients. MoAb was started 15 days post-BMT and given for 14 days at 10 mg/d; two patients developed acute GVHD, the other did not.27 Additional studies are necessary. Furthermore, synergistic effects of anti-IL-2R MoAb with subtherapeutic doses (1 to 2 mg/kg) of CSP have been observed in other model^.^***^ Conceivably, similar combinations could be used in BMT, thereby ameliorating or eliminating CSP-related toxicity.
anisms leading to acute GVHD* as of the role of CYtokines in the Pathogenesis of the graft-host alloreaction, might further clarify the role of these MoAbs in prevention and treatment of acute GVHD.
